Cardiff Oncology shares plunge after Q2 earnings miss
Carol Lindstrom, a director at Genpact Ltd (NYSE:G), recently sold 4,916 common shares of the company on February 11, 2025. The shares were sold at a price of $54.40 per share, bringing the total transaction value to $267,430. Following this sale, Lindstrom retains ownership of 18,686 shares in the company. The transaction comes as Genpact’s stock trades near its 52-week high of $56.76, having delivered an impressive 59% return over the past year. While this insider sale occurred, InvestingPro data shows management has been actively buying back shares, suggesting continued confidence in the company’s prospects. For deeper insights into insider trading patterns and 15+ additional ProTips, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Genpact Ltd. has been receiving positive attention from several financial firms following strong earnings and revenue results. Mizuho (NYSE:MFG) Securities increased Genpact’s price target to $55, citing the company’s successful fourth-quarter results for 2024 and optimistic guidance for 2025. BMO Capital Markets also raised its price target for Genpact to $58, acknowledging the company’s consistent performance throughout 2024, especially in terms of revenue.
On a similar note, Needham maintained a Buy rating on Genpact and increased the price target to $65, following the company’s strong performance in the fourth quarter of FY24. BofA Securities analyst Kunal Tayal also raised the price target for Genpact to $58, noting a year-over-year increase of 7% in the third quarter, mainly driven by the company’s Data-Tech-AI segment.
These recent developments are significant as Genpact continues to impress with its earnings and revenue growth. The company’s fourth-quarter earnings per share (EPS) of $0.91 surpassed the analyst estimate of $0.86, and its revenue for the quarter was reported at $1.25 billion, exceeding the consensus estimate of $1.23 billion. Additionally, Genpact’s optimistic guidance for the first quarter of 2025 anticipates an EPS of $0.79-$0.80, and revenue projections of $1.202-1.213 billion, both higher than consensus estimates.
These positive financial results and favorable analyst reviews reflect the company’s successful execution of strategic initiatives and its potential for sustained growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.